Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ATX.AU
- Price
- 0.07
- Stock movement down
- -0.00 (-2.99%)
- Company name
- Amplia Therapeutics Ltd
- Exchange
- (AU ,
- Currency
- AUD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 25.03M
- Ent value
- 25.07M
- Price/Sales
- 15.86
- Price/Book
- 2.19
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -11.76%
- 1 year return
- -9.09%
- 3 year return
- -21.31%
- 5 year return
- 4.05%
- 10 year return
- -43.12%
Last updated: 2025-04-04
DIVIDENDS
ATX.AU does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 15.86 |
| Price to Book | 2.19 |
| EV to Sales | 15.88 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 385.13M |
| EPS (TTM) | -0.05 |
| FCF per share (TTM) | -0.03 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.58M |
| Gross profit (TTM) | 1.32M |
| Operating income (TTM) | -13.51M |
| Net income (TTM) | -9.50M |
| EPS (TTM) | -0.05 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 83.48% |
| Operating margin (TTM) | -855.69% |
| Profit margin (TTM) | -601.78% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 3.39M |
| Net receivables | 3.18M |
| Total current assets | 6.75M |
| Goodwill | 0.00 |
| Intangible assets | 7.94M |
| Property, plant and equipment | 100.92K |
| Total assets | 14.85M |
| Accounts payable | 1.60M |
| Short/Current long term debt | 1.59M |
| Total current liabilities | 3.40M |
| Total liabilities | 3.43M |
| Shareholder's equity | 11.42M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -8.66M |
| Capital expenditures (TTM) | 8.04K |
| Free cash flow (TTM) | -5.13M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -83.19% |
| Return on Assets | -63.99% |
| Return on Invested Capital | -73.26% |
| Cash Return on Invested Capital | -39.56% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.07 |
| Daily high | 0.07 |
| Daily low | 0.06 |
| Daily Volume | 1.48M |
| All-time high | 168.60 |
| 1y analyst estimate | 0.24 |
| Beta | 0.78 |
| EPS (TTM) | -0.05 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 28 May 2025 |
Downside potential
Loading...
Downside potential data
| ATX.AU | S&P500 | |
| Current price drop from All-time high | -99.96% | -12.44% |
| Highest price drop | -99.97% | -56.47% |
| Date of highest drop | 19 Mar 2020 | 9 Mar 2009 |
| Avg drop from high | -79.20% | -11.07% |
| Avg time to new high | 46 days | 12 days |
| Max time to new high | 1970 days | 1805 days |
COMPANY DETAILS
Marketcap
25.03M
Marketcap category
Small-cap
Description
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial. It also develops AMP886, which is in preclinical trial for treating solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Australia
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found